Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

Editor’s introduction to the initial issue of the ninth volume of GaBI Journal / Professor Philip D Walson, MD

Commentary

Importance of the determination of the higher order structure in the in-use stability studies of biopharmaceuticals / Professor Alain Astier, PharmD, PhD

Original Research

Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions / Shon Crampton, BA; Alla Polozova, PhD; Darin Asbury, BS; Alexis Lueras, BS; Paul Breslin, BS; Jane Hippenmeyer, PharmD; Jennifer Litowski, PhD; Monica Goss, PhD

Pharmaceutical pricing policy in Saudi Arabia: findings and implications / Alian A Alrasheedy, BPharm(Hons), MPharm(Clin), PhD, MACP, RPh

Review Article

Current trends for biosimilars in the Latin American market / Esteban Ortiz-Prado, Jorge Ponce-Zea, Eduardo Vasconez, Diana Castillo, Diana Checa, Nathalia Rodríguez-Burneo, Felipe Andrade, Damaris Intriago, Claudio Galarza-Maldonado

Legal

It is time to change US trade policy to foster access to medicines / Maria Fabiana Jorge, MBA

Policy recommendations for a sustainable biosimilars market: lessons from Europe / Professor Philip J Schneider, MS, FASHP, FFIP; Michael S Reilly, Esq

Perspective

An evolving role for non-governmental organizations dealing with registration backlogs and rising costs: the example of cancer biosimilars in South Africa / Paul Malherbe, PhD

Regulatory

Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD

Opinion

Overview of non-innovator biological products in India / GR Soni, PhD

Meeting Report

3rd Colombian educational workshop on regulatory assessment of biosimilars 2019 – Report

Pharma News

Top developments in biosimilars during 2019 / GaBI Journal Editor

Research News

Poor traceability of biologicals in UK ADR reporting indicates the need for improvements to ensure patient safety / Kevin Klein, PhD

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Last update: 2020-03-25 Go Back Print

Comments are closed.